CY1118843T1 - Παραλλαγμενες ανασυνδυασμενες πρωτεϊνες βητα-γλυκοκερεβροσιδασης με αυξημενη σταθεροτητα και αυξημενη συγκρατουμενη καταλυτικη δραστικοτητα - Google Patents

Παραλλαγμενες ανασυνδυασμενες πρωτεϊνες βητα-γλυκοκερεβροσιδασης με αυξημενη σταθεροτητα και αυξημενη συγκρατουμενη καταλυτικη δραστικοτητα

Info

Publication number
CY1118843T1
CY1118843T1 CY20161101239T CY161101239T CY1118843T1 CY 1118843 T1 CY1118843 T1 CY 1118843T1 CY 20161101239 T CY20161101239 T CY 20161101239T CY 161101239 T CY161101239 T CY 161101239T CY 1118843 T1 CY1118843 T1 CY 1118843T1
Authority
CY
Cyprus
Prior art keywords
proteins
increased
recombinant
glucocerebrosidase
glykerobreossible
Prior art date
Application number
CY20161101239T
Other languages
English (en)
Inventor
Hung Do
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of CY1118843T1 publication Critical patent/CY1118843T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Εδώ περιγράφονται παραλλαγμένες, ανασυνδυασμένες πρωτεΐνες β-γλυκοκερεβροσιδάσης που χαρακτηρίζονται από το ότι έχουν αυξημένη σταθερότητα σε σχέση με την ανασυνδυασμένη β-γλυκοκερεβροσιδάση άγριου-τύπου. Επίσης παρέχονται εδώ παραλλαγμένες, ανασυνδυασμένες πρωτεΐνες β-γλυκοκερεβροσιδάσης που χαρακτηρίζονται από το ότι συγκρατούν περισσότερη καταλυτική δραστικότητα σε σχέση με την ανασυνδυασμένη β-γλυκοκερεβροσιδάση άγριου τύπου. Επιπλέον εδώ περιγράφονται παραλλαγμένες, ανασυνδυασμένες πρωτεΐνες β- γλυκοκερεβροσιδάσης που μπορούν να έχουν παραλλαγές αμινοξέων σε μία ή περισσότερες από τις ακόλουθες θέσεις: 316, 317, 321 και 145. Περιγράφονται επίσης οι μέθοδοι παρασκευής των παραλλαγμένων, ανασυνδυασμένων πρωτεϊνών β-γλυκοκερεβροσιδάσης, καθώς και οι μέθοδοι θεραπείας ασθενών με νόσους λυσοσωματικής αποθήκευσης.
CY20161101239T 2010-11-08 2016-11-29 Παραλλαγμενες ανασυνδυασμενες πρωτεϊνες βητα-γλυκοκερεβροσιδασης με αυξημενη σταθεροτητα και αυξημενη συγκρατουμενη καταλυτικη δραστικοτητα CY1118843T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41133110P 2010-11-08 2010-11-08
US41218010P 2010-11-10 2010-11-10
PCT/US2011/059731 WO2012064709A2 (en) 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity

Publications (1)

Publication Number Publication Date
CY1118843T1 true CY1118843T1 (el) 2018-01-10

Family

ID=46051505

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101239T CY1118843T1 (el) 2010-11-08 2016-11-29 Παραλλαγμενες ανασυνδυασμενες πρωτεϊνες βητα-γλυκοκερεβροσιδασης με αυξημενη σταθεροτητα και αυξημενη συγκρατουμενη καταλυτικη δραστικοτητα

Country Status (19)

Country Link
US (4) US8962564B2 (el)
EP (2) EP3144386B1 (el)
JP (2) JP6073796B2 (el)
KR (1) KR101901467B1 (el)
CN (2) CN103314105B (el)
BR (1) BR112013011152A2 (el)
CA (1) CA2817011C (el)
CY (1) CY1118843T1 (el)
DK (1) DK2638152T3 (el)
ES (2) ES2604490T3 (el)
HR (1) HRP20161560T1 (el)
HU (1) HUE030932T2 (el)
LT (1) LT2638152T (el)
PL (1) PL2638152T3 (el)
PT (1) PT2638152T (el)
RS (1) RS55405B1 (el)
SI (1) SI2638152T1 (el)
SM (1) SMT201600431B (el)
WO (1) WO2012064709A2 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127162A1 (en) 2019-02-01 2020-08-06 Oxyrane Uk Ltd Glucocerebrosidase polypeptides
CN114364794A (zh) * 2019-09-09 2022-04-15 豪夫迈·罗氏有限公司 葡糖脑苷脂酶突变体
KR20230042513A (ko) * 2020-07-29 2023-03-28 프리라인 테라퓨틱스 리미티드 폴리펩티드
WO2023145812A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 グルコセレブロシダーゼ活性を有する糖鎖付加タンパク質
WO2023145813A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 グルコセレブロシダーゼ活性を有するタンパク質およびその製造方法
WO2023145814A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 向上した酵素活性または向上した安定性を有する組換えグルコセレブロシダーゼタンパク質
WO2023198661A1 (en) 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
WO2024074142A1 (en) * 2022-10-08 2024-04-11 Lingyi Biotech Co., Ltd. Polynucleotides for the treatment of disease associated with gcase deficiency

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503721A (ja) * 1988-12-23 1991-08-22 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
ES2093642T3 (es) 1988-12-23 1997-01-01 Genzyme Corp Celulas cho que producen gluco-cerebrosidasa re-combinante enzimaticamente activa.
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
EP0979311A1 (en) 1997-04-30 2000-02-16 Of The University Of Minnesota Regents $i(IN VIVO) USE OF RECOMBINAGENIC OLIGONUCLEOBASES TO CORRECT GENETIC LESIONS IN HEPATOCYTES
DE69835367T2 (de) 1997-10-29 2007-08-02 Genzyme Corp., Framingham Gentherapie für gaucher-krankheit
AU764686B2 (en) 1998-08-28 2003-08-28 Duke University Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences
EP1246915A2 (en) * 1999-12-30 2002-10-09 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
WO2001077307A2 (en) * 2000-04-06 2001-10-18 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
WO2002002597A2 (en) * 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
WO2004091475A2 (en) * 2003-04-16 2004-10-28 Yeda Research And Development Co. Ltd. Gaucher disease drugs and methods of identifying same
WO2005089047A2 (en) 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
MX2009011473A (es) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
CN104530068B (zh) * 2007-05-22 2017-05-03 阿米库斯治疗学公司 用于制备异法戈明的化合物
EP2220218A4 (en) 2007-11-02 2010-12-08 Scripps Research Inst BORONIC AMINO ACID GENETICALLY CODED
MX2010004807A (es) 2007-11-02 2010-08-02 Scripss Res Inst Evolucion dirigida utilizando proteinas que comprenden aminoacidos no naturales.

Also Published As

Publication number Publication date
CN103314105A (zh) 2013-09-18
JP2017099390A (ja) 2017-06-08
CA2817011A1 (en) 2012-05-18
RS55405B1 (sr) 2017-04-28
EP3144386B1 (en) 2019-05-29
SMT201600431B (it) 2017-01-10
EP2638152A2 (en) 2013-09-18
ES2604490T3 (es) 2017-03-07
JP6457559B2 (ja) 2019-01-23
PT2638152T (pt) 2016-10-25
KR20140009238A (ko) 2014-01-22
JP6073796B2 (ja) 2017-02-01
CN103314105B (zh) 2015-11-25
KR101901467B1 (ko) 2018-11-02
US20130344054A1 (en) 2013-12-26
SI2638152T1 (sl) 2016-12-30
EP2638152B1 (en) 2016-08-31
HUE030932T2 (en) 2017-06-28
WO2012064709A2 (en) 2012-05-18
US9254313B2 (en) 2016-02-09
CA2817011C (en) 2019-04-02
LT2638152T (lt) 2016-12-12
PL2638152T3 (pl) 2017-02-28
US20150216950A1 (en) 2015-08-06
US20170157220A1 (en) 2017-06-08
US9566316B2 (en) 2017-02-14
EP2638152A4 (en) 2014-04-09
CN105296447A (zh) 2016-02-03
US8962564B2 (en) 2015-02-24
WO2012064709A3 (en) 2012-08-02
HRP20161560T1 (hr) 2016-12-30
ES2743825T3 (es) 2020-02-20
JP2014500722A (ja) 2014-01-16
EP3144386A1 (en) 2017-03-22
DK2638152T3 (en) 2016-12-12
US9821038B2 (en) 2017-11-21
US20160184408A1 (en) 2016-06-30
BR112013011152A2 (pt) 2016-11-29

Similar Documents

Publication Publication Date Title
CY1118843T1 (el) Παραλλαγμενες ανασυνδυασμενες πρωτεϊνες βητα-γλυκοκερεβροσιδασης με αυξημενη σταθεροτητα και αυξημενη συγκρατουμενη καταλυτικη δραστικοτητα
CY1124154T1 (el) Παραδοση θεραπευτικων παραγοντων στο κνς
CY1124332T1 (el) Πεγκυλιωμενες ενωσεις ανασυνδυασμενης ανθρωπινης αυξητικης ορμονης
CY1120337T1 (el) Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
CY1124138T1 (el) Παραλλαγμενες μορφες της ουρικης οξειδασης και χρηση αυτων
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
CY1118105T1 (el) Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
BR112015014752A2 (pt) compostos e métodos para modulação de cinase, e indicações para isto
NZ627528A (en) Peptidomimetic macrocycles
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
MX357803B (es) Moléculas de ácido nucleico artificiales.
MX2012013375A (es) Peptido c pegilado.
MX2019002345A (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
WO2014039585A3 (en) Chimeric polypeptides having targeted binding specificity
DE60332355D1 (de) Hla-a24-restringiertes krebsantigenpeptid
NZ596658A (en) Dig-10 insecticidal cry toxins
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
IN2012DN02981A (el)
CY1119930T1 (el) Λευκολεκτινες και χρησεις αυτων
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.